NO20076067L - Metoder for syntese av substituerte 3-cyanokinoliner og mellomprodukter av denne - Google Patents
Metoder for syntese av substituerte 3-cyanokinoliner og mellomprodukter av denneInfo
- Publication number
- NO20076067L NO20076067L NO20076067A NO20076067A NO20076067L NO 20076067 L NO20076067 L NO 20076067L NO 20076067 A NO20076067 A NO 20076067A NO 20076067 A NO20076067 A NO 20076067A NO 20076067 L NO20076067 L NO 20076067L
- Authority
- NO
- Norway
- Prior art keywords
- cyanoquinolines
- methods
- substituted
- intermediates
- synthesis
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 2
- QZZYYBQGTSGDPP-UHFFFAOYSA-N quinoline-3-carbonitrile Chemical class C1=CC=CC2=CC(C#N)=CN=C21 QZZYYBQGTSGDPP-UHFFFAOYSA-N 0.000 title abstract 2
- 230000015572 biosynthetic process Effects 0.000 title 1
- 239000000543 intermediate Substances 0.000 title 1
- 238000003786 synthesis reaction Methods 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
- C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Quinoline Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US68439105P | 2005-05-25 | 2005-05-25 | |
| PCT/US2006/016215 WO2006127207A1 (en) | 2005-05-25 | 2006-04-28 | Methods of synthesizing substituted 3-cyanoquinolines and intermediates thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20076067L true NO20076067L (no) | 2007-12-21 |
Family
ID=37037465
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20076067A NO20076067L (no) | 2005-05-25 | 2007-11-26 | Metoder for syntese av substituerte 3-cyanokinoliner og mellomprodukter av denne |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US20060270668A1 (es) |
| EP (1) | EP1883631A1 (es) |
| JP (1) | JP2008545688A (es) |
| KR (1) | KR20080016671A (es) |
| CN (1) | CN101203494A (es) |
| AR (1) | AR053872A1 (es) |
| AU (1) | AU2006249600A1 (es) |
| BR (1) | BRPI0610147A2 (es) |
| CA (1) | CA2609186A1 (es) |
| CR (1) | CR9544A (es) |
| GT (1) | GT200600213A (es) |
| IL (1) | IL187532A0 (es) |
| NO (1) | NO20076067L (es) |
| PA (1) | PA8676201A1 (es) |
| PE (1) | PE20061417A1 (es) |
| RU (1) | RU2007143161A (es) |
| TW (1) | TW200716557A (es) |
| WO (1) | WO2006127207A1 (es) |
| ZA (1) | ZA200710148B (es) |
Families Citing this family (76)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100926247B1 (ko) * | 2001-02-24 | 2009-11-12 | 베링거 잉겔하임 파르마 게엠베하 운트 코 카게 | 크산틴 유도체를 포함하는 약제학적 조성물 및 이의제조방법 |
| US7407955B2 (en) | 2002-08-21 | 2008-08-05 | Boehringer Ingelheim Pharma Gmbh & Co., Kg | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
| US7501426B2 (en) | 2004-02-18 | 2009-03-10 | Boehringer Ingelheim International Gmbh | 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions |
| DE102004054054A1 (de) | 2004-11-05 | 2006-05-11 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine |
| ES2364495T3 (es) | 2005-02-03 | 2011-09-05 | The General Hospital Corporation | Método para tratar cáncer resistente a gefitinib. |
| DE102005035891A1 (de) * | 2005-07-30 | 2007-02-08 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel |
| JP2009514870A (ja) | 2005-11-04 | 2009-04-09 | ワイス | ｍＴＯＲインヒビター、ハーセプチン、および／またはＨＫＩ−２７２の抗悪性腫瘍性組み合わせ |
| CA2833706C (en) | 2005-11-11 | 2014-10-21 | Boehringer Ingelheim International Gmbh | Quinazoline derivatives for the treatment of cancer diseases |
| EP1852108A1 (en) | 2006-05-04 | 2007-11-07 | Boehringer Ingelheim Pharma GmbH & Co.KG | DPP IV inhibitor formulations |
| PE20110235A1 (es) | 2006-05-04 | 2011-04-14 | Boehringer Ingelheim Int | Combinaciones farmaceuticas que comprenden linagliptina y metmorfina |
| KR101452915B1 (ko) | 2006-05-04 | 2014-10-21 | 베링거 인겔하임 인터내셔날 게엠베하 | 다형태 |
| AU2013202912B2 (en) * | 2007-06-08 | 2016-10-27 | Firmenich Incorporated | Modulation of chemosensory receptors and ligands associated therewith |
| AU2013203571B2 (en) * | 2007-10-17 | 2016-06-16 | Wyeth Llc | Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl} -4-(dimethylamino)-2-butenamide and crystalline forms thereof |
| US8022216B2 (en) * | 2007-10-17 | 2011-09-20 | Wyeth Llc | Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof |
| AU2016225895B2 (en) * | 2007-10-17 | 2018-02-08 | Wyeth Llc | Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl} -4-)dimethylamino)-2-butenamide and crystalline forms thereof |
| JP2009215259A (ja) * | 2008-03-12 | 2009-09-24 | Ube Ind Ltd | ３−ハロゲノ−４−ヒドロカルビルオキシニトロベンゼン化合物の製造方法 |
| PE20091730A1 (es) | 2008-04-03 | 2009-12-10 | Boehringer Ingelheim Int | Formulaciones que comprenden un inhibidor de dpp4 |
| WO2009151910A2 (en) * | 2008-05-25 | 2009-12-17 | Wyeth | Combination product of receptor tyrosine kinase inhibitor and fatty acid synthase inhibitor for treating cancer |
| ES2692769T3 (es) | 2008-06-17 | 2018-12-05 | Wyeth Llc | Combinaciones antineoplásicas que contienen HKI-272 y vinorelbina |
| KR101577159B1 (ko) | 2008-07-31 | 2015-12-11 | 세노믹스, 인코포레이티드 | 단맛 향상제의 제조 방법 및 중간체 |
| CN105147713A (zh) | 2008-08-04 | 2015-12-16 | 惠氏有限责任公司 | 4-苯胺基-3-氰基喹啉和卡培他滨的抗肿瘤组合 |
| KR20190016601A (ko) | 2008-08-06 | 2019-02-18 | 베링거 인겔하임 인터내셔날 게엠베하 | 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료 |
| UY32030A (es) | 2008-08-06 | 2010-03-26 | Boehringer Ingelheim Int | "tratamiento para diabetes en pacientes inapropiados para terapia con metformina" |
| CA2736421A1 (en) | 2008-09-10 | 2010-03-18 | Boehringer Ingelheim International Gmbh | Combination therapy for the treatment of diabetes and related conditions |
| US20200155558A1 (en) | 2018-11-20 | 2020-05-21 | Boehringer Ingelheim International Gmbh | Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug |
| CN101723854A (zh) * | 2008-10-24 | 2010-06-09 | 上海特化医药科技有限公司 | 6-取代氨基-3-氰基喹啉类化合物的制备方法及其中间体 |
| JP2012512848A (ja) | 2008-12-23 | 2012-06-07 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 有機化合物の塩の形態 |
| TW201036975A (en) | 2009-01-07 | 2010-10-16 | Boehringer Ingelheim Int | Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy |
| SG174382A1 (en) | 2009-04-06 | 2011-11-28 | Wyeth Llc | Treatment regimen utilizing neratinib for breast cancer |
| PL2451445T3 (pl) | 2009-07-06 | 2019-09-30 | Boehringer Ingelheim International Gmbh | Sposób suszenia BIBW2992, jego soli i stałych preparatów farmaceutycznych zawierających tę substancję czynną |
| KR20240090632A (ko) | 2009-11-27 | 2024-06-21 | 베링거 인겔하임 인터내셔날 게엠베하 | 리나글립틴과 같은 ｄｐｐ－ｉｖ 억제제를 사용한 유전자형 검사된 당뇨병 환자의 치료 |
| CA3070513C (en) | 2010-05-05 | 2023-01-03 | Boehringer Ingelheim International Gmbh | A dpp-4 inhibitor for use in treatment of skin-alterations or necrosis |
| KR20130093012A (ko) | 2010-06-24 | 2013-08-21 | 베링거 인겔하임 인터내셔날 게엠베하 | 당뇨병 요법 |
| AR083878A1 (es) | 2010-11-15 | 2013-03-27 | Boehringer Ingelheim Int | Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento |
| BR112013022552B1 (pt) * | 2011-03-04 | 2021-11-23 | Newgen Therapeutics, Inc | Compostos de quinazolina substituídos com alcino, seu uso, composição farmacêutica, e kit |
| CN102718749A (zh) * | 2011-03-30 | 2012-10-10 | 北京德众万全药物技术开发有限公司 | 抗肿瘤药物诺那替尼的制备方法 |
| CN102718679B (zh) * | 2011-03-30 | 2016-06-08 | 北京万全阳光医药科技有限公司 | 一种诺那替尼关键中间体的制备方法 |
| WO2012155339A1 (zh) | 2011-05-17 | 2012-11-22 | 江苏康缘药业股份有限公司 | 4-苯胺-6-丁烯酰胺-7-烷醚喹唑啉衍生物及其制备方法和用途 |
| DK2731947T3 (en) | 2011-07-15 | 2019-04-23 | Boehringer Ingelheim Int | SUBSTITUTED DIMERIC QUINAZOLINE DERIVATIVE, PREPARATION AND USE thereof IN PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF TYPE I AND TYPE II DIABETES |
| US9555001B2 (en) | 2012-03-07 | 2017-01-31 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition and uses thereof |
| WO2013171166A1 (en) | 2012-05-14 | 2013-11-21 | Boehringer Ingelheim International Gmbh | A xanthine derivative as dpp-4 inhibitor for use in the treatment of sirs and/or sepsis |
| WO2013171167A1 (en) | 2012-05-14 | 2013-11-21 | Boehringer Ingelheim International Gmbh | A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome |
| WO2013174767A1 (en) | 2012-05-24 | 2013-11-28 | Boehringer Ingelheim International Gmbh | A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference |
| PE20191204A1 (es) | 2012-08-06 | 2019-09-10 | Firmenich Incorporated | Modificador del sabor dulce |
| CN103588755B (zh) * | 2012-08-17 | 2016-06-22 | 正大天晴药业集团股份有限公司 | Neratinib的制备方法 |
| JP6669499B2 (ja) | 2013-02-15 | 2020-03-18 | カラ ファーマシューティカルズ インコーポレイテッド | 治療用化合物 |
| JO3155B1 (ar) | 2013-02-19 | 2017-09-20 | Senomyx Inc | معدِّل نكهة حلوة |
| JP2016510000A (ja) | 2013-02-20 | 2016-04-04 | カラ ファーマシューティカルズ インコーポレイテッド | 治療用化合物およびその使用 |
| US9688688B2 (en) | 2013-02-20 | 2017-06-27 | Kala Pharmaceuticals, Inc. | Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof |
| CN103265530A (zh) * | 2013-06-14 | 2013-08-28 | 苏州明锐医药科技有限公司 | 来那替尼的制备方法 |
| US9890173B2 (en) | 2013-11-01 | 2018-02-13 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
| NZ719185A (en) | 2013-11-01 | 2017-11-24 | Kala Pharmaceuticals Inc | Crystalline forms of therapeutic compounds and uses thereof |
| US9242965B2 (en) | 2013-12-31 | 2016-01-26 | Boehringer Ingelheim International Gmbh | Process for the manufacture of (E)-4-N,N-dialkylamino crotonic acid in HX salt form and use thereof for synthesis of EGFR tyrosine kinase inhibitors |
| EP3110449B1 (en) | 2014-02-28 | 2023-06-28 | Boehringer Ingelheim International GmbH | Medical use of a dpp-4 inhibitor |
| CN105367552A (zh) * | 2015-01-09 | 2016-03-02 | 苏州晶云药物科技有限公司 | 来那替尼马来酸盐的新晶型及其制备方法 |
| CN105461689B (zh) * | 2015-05-19 | 2018-12-04 | 上海麦步医药科技有限公司 | 一种表皮生长因子受体(egfr)抑制剂来那替尼的新型制备方法 |
| CN105085485B (zh) * | 2015-08-21 | 2017-08-29 | 哈尔滨珍宝制药有限公司 | 一种来那替尼的制备方法 |
| CN105330646B (zh) * | 2015-12-04 | 2019-05-24 | 上海勋和医药科技有限公司 | 一种抗肿瘤药马来酸来那替尼的制备方法 |
| EP4233840A3 (en) | 2016-06-10 | 2023-10-18 | Boehringer Ingelheim International GmbH | Combinations of linagliptin and metformin |
| CN105949176B (zh) * | 2016-06-24 | 2018-10-26 | 浙江海正药业股份有限公司 | 一种来那替尼的纯化方法 |
| US20200308141A1 (en) | 2016-06-27 | 2020-10-01 | Pliva Hrvatska D.O.O. | Solid state forms of neratinib and salts thereof |
| CN106220560A (zh) * | 2016-07-27 | 2016-12-14 | 华侨大学 | 一种多取代喹啉衍生物的制备方法 |
| EP3509423A4 (en) | 2016-09-08 | 2020-05-13 | Kala Pharmaceuticals, Inc. | CRYSTALLINE FORMS OF THERAPEUTIC COMPOUNDS AND USES THEREOF |
| KR20190051010A (ko) | 2016-09-08 | 2019-05-14 | 칼라 파마슈티컬스, 인크. | 치료 화합물의 결정형 및 그의 용도 |
| AU2017324713B2 (en) | 2016-09-08 | 2020-08-13 | KALA BIO, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
| EP3700889A4 (en) * | 2017-11-20 | 2020-09-02 | Teligene Ltd. | (E) -N- (3-CYANO-7-ETOXY-4 - ((4-PHENOXYPHENYL) AMINO) QUINOLIN-6-YL) -4- (DIMETHYLAMINO) BUT-2-ENAMIDE AND THEIR CRYSTALLINE FORMS SALTS |
| CN108285421A (zh) * | 2018-01-26 | 2018-07-17 | 黑龙江鑫创生物科技开发有限公司 | 一种微通道反应器合成拉帕替尼中间体的方法 |
| CN110357854A (zh) * | 2018-03-26 | 2019-10-22 | 江苏创诺制药有限公司 | 一种来那替尼的制备方法 |
| CN108373467A (zh) * | 2018-04-27 | 2018-08-07 | 江苏创诺制药有限公司 | 来那替尼游离碱晶型及制备方法 |
| JP7453210B2 (ja) | 2018-08-07 | 2024-03-19 | フィルメニッヒ インコーポレイテッド | ５－置換４－アミノ－１Ｈ－ベンゾ［ｃ］［１，２，６］チアジアジン２，２－ジオキシド並びにその配合物及び使用 |
| CN109320686B (zh) * | 2018-08-29 | 2021-06-08 | 华南理工大学 | 一种聚异脲类聚合物及其制备方法和应用 |
| CN112679473B (zh) * | 2019-10-18 | 2024-03-05 | 四川科伦药物研究院有限公司 | 来那替尼中间体晶体、制备方法及其用途 |
| CN111875539B (zh) * | 2020-07-15 | 2022-06-21 | 苏中药业集团股份有限公司 | 一种egfr类分子靶向抗肿瘤药物的制备方法 |
| CN111848581B (zh) * | 2020-08-19 | 2021-08-10 | 昆明学院 | 3-氰基-4-苯胺基-6-氨基喹啉衍生物的制备方法 |
| CN111848582A (zh) * | 2020-08-19 | 2020-10-30 | 重庆医科大学 | 制备表皮生长因子受体抑制剂来那替尼有关物质的方法 |
| KR102713340B1 (ko) * | 2022-11-08 | 2024-10-02 | 경희대학교 산학협력단 | 고리화첨가 반응과 고리축소 반응의 연속 반응을 이용한 피롤로[1,2-a]퀴놀린의 제조방법 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA73073C2 (uk) * | 1997-04-03 | 2005-06-15 | Уайт Холдінгз Корпорейшн | Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція |
| US6002008A (en) * | 1997-04-03 | 1999-12-14 | American Cyanamid Company | Substituted 3-cyano quinolines |
| US6297258B1 (en) * | 1998-09-29 | 2001-10-02 | American Cyanamid Company | Substituted 3-cyanoquinolines |
| BR9914167B1 (pt) * | 1998-09-29 | 2011-03-09 | compostos e composições farmacêuticas compreendendo 3-ciano quinolinas substituìdas. | |
| US6288082B1 (en) * | 1998-09-29 | 2001-09-11 | American Cyanamid Company | Substituted 3-cyanoquinolines |
| US6384051B1 (en) * | 2000-03-13 | 2002-05-07 | American Cyanamid Company | Method of treating or inhibiting colonic polyps |
| UA77200C2 (en) * | 2001-08-07 | 2006-11-15 | Wyeth Corp | Antineoplastic combination of cci-779 and bkb-569 |
| CA2475141A1 (en) * | 2002-02-05 | 2003-08-14 | Wyeth | Process for the synthesis of n-acyl-2-amino-4-alkoxy-5-nitrobenzoic acids |
| CL2004000016A1 (es) * | 2003-01-21 | 2005-04-15 | Wyeth Corp | Compuesto derivado de cloruro de 4-amino-2-butenoilo o una sal farmaceuticamente aceptable del mismo; procedimiento para preparar dicho compuesto, util como intermediario en la sintesis de compuestos inhibidores de proteina quinasa tirosina. |
| AU2004267061A1 (en) * | 2003-08-19 | 2005-03-03 | Wyeth Holdings Corporation | Process for the preparation of 4-amino-3-quinolinecarbonitriles |
| BR0318503A (pt) * | 2003-09-15 | 2006-09-12 | Wyeth Corp | quinolinas substituìdas como inibidores de enzima proteìna tirosina cinase |
| US7365203B2 (en) * | 2003-09-15 | 2008-04-29 | Wyeth | Process for the synthesis of 6-amino-4-(3-chloro-4-fluoro-phenylamino)-7-ethoxy-quinoline-3-carbonitrile |
| US7399865B2 (en) * | 2003-09-15 | 2008-07-15 | Wyeth | Protein tyrosine kinase enzyme inhibitors |
| US7432377B2 (en) * | 2004-01-16 | 2008-10-07 | Wyeth | Quinoline intermediates of receptor tyrosine kinase inhibitors and the synthesis thereof |
-
2006
- 2006-04-28 BR BRPI0610147-0A patent/BRPI0610147A2/pt not_active IP Right Cessation
- 2006-04-28 WO PCT/US2006/016215 patent/WO2006127207A1/en not_active Ceased
- 2006-04-28 AU AU2006249600A patent/AU2006249600A1/en not_active Abandoned
- 2006-04-28 TW TW095115306A patent/TW200716557A/zh unknown
- 2006-04-28 EP EP06769913A patent/EP1883631A1/en not_active Withdrawn
- 2006-04-28 JP JP2008513498A patent/JP2008545688A/ja not_active Withdrawn
- 2006-04-28 RU RU2007143161/04A patent/RU2007143161A/ru unknown
- 2006-04-28 CN CNA2006800220965A patent/CN101203494A/zh active Pending
- 2006-04-28 KR KR1020077030160A patent/KR20080016671A/ko not_active Withdrawn
- 2006-04-28 CA CA002609186A patent/CA2609186A1/en not_active Abandoned
- 2006-05-18 AR ARP060102010A patent/AR053872A1/es unknown
- 2006-05-22 GT GT200600213A patent/GT200600213A/es unknown
- 2006-05-22 PE PE2006000534A patent/PE20061417A1/es not_active Application Discontinuation
- 2006-05-25 US US11/439,984 patent/US20060270668A1/en not_active Abandoned
- 2006-05-25 PA PA20068676201A patent/PA8676201A1/es unknown
-
2007
- 2007-11-20 IL IL187532A patent/IL187532A0/en unknown
- 2007-11-23 CR CR9544A patent/CR9544A/es unknown
- 2007-11-26 NO NO20076067A patent/NO20076067L/no not_active Application Discontinuation
- 2007-11-26 ZA ZA200710148A patent/ZA200710148B/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AR053872A1 (es) | 2007-05-23 |
| CR9544A (es) | 2008-03-07 |
| US20060270668A1 (en) | 2006-11-30 |
| JP2008545688A (ja) | 2008-12-18 |
| EP1883631A1 (en) | 2008-02-06 |
| WO2006127207A1 (en) | 2006-11-30 |
| GT200600213A (es) | 2007-01-12 |
| PA8676201A1 (es) | 2009-03-31 |
| KR20080016671A (ko) | 2008-02-21 |
| AU2006249600A1 (en) | 2006-11-30 |
| BRPI0610147A2 (pt) | 2010-06-01 |
| PE20061417A1 (es) | 2007-01-20 |
| CN101203494A (zh) | 2008-06-18 |
| IL187532A0 (en) | 2008-03-20 |
| ZA200710148B (en) | 2008-09-25 |
| TW200716557A (en) | 2007-05-01 |
| CA2609186A1 (en) | 2006-11-30 |
| RU2007143161A (ru) | 2009-07-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20076067L (no) | Metoder for syntese av substituerte 3-cyanokinoliner og mellomprodukter av denne | |
| ATE362932T1 (de) | Azaindolverbindungen als kinaseinhibitoren | |
| JO3007B1 (ar) | مركبات و تركيبات كمثبطات كيناز بروتين | |
| MY153915A (en) | Organic compounds | |
| MA32508B1 (fr) | Composes organiques | |
| NO20073182L (no) | Indazol-karboksamidforbindelser | |
| NO20070489L (no) | 3-aminocyklopentankarboksamider som modulatorer av kjemokinreseptorer. | |
| EA201000149A1 (ru) | Производные 1-фенил-2-пиридинилалкиловых спиртов в качестве ингибиторов фосфодиэстераз | |
| EA200801362A1 (ru) | Пиримидинил бензотиофеновые соединения | |
| EA201790678A1 (ru) | Бициклические гетероарильные соединения | |
| MX2010004705A (es) | Derivados de piridazinona y uso de los mismos como inhibidores del receptor p2x7. | |
| EA200700168A1 (ru) | Производные замещенной циклической мочевины, их получение и их фармацевтическое применение в качестве ингибиторов киназы | |
| TW200740844A (en) | Novel MAdCAM antibodies | |
| EA200801291A1 (ru) | Карбониламинопирролопиразолы в качестве эффективных ингибиторов киназ | |
| EA201170531A1 (ru) | Соединения на основе пиридина и пиримидина в качестве ингибиторов сигнального пути wnt для лечения рака | |
| NO20075643L (no) | Fremgangsmater for fremstilling av 3-cyano-kinoliner og derved fremstilte mellomprodukter | |
| NO20082285L (no) | 3-aminosyklopentankarboksamider som modulatorer av kjemokinreseptorer | |
| EA200601391A1 (ru) | Производные хинолина для применения в качестве микобактериальных ингибиторов | |
| EA201270256A1 (ru) | Производные т1-замещенного 5-фтор-2-оксопиримидинон-1 (2h) -карбоксамида | |
| UA90706C2 (ru) | Антагонисты рецептора pgd2 для лечения воспалительных заболеваний | |
| NO20065052L (no) | Krystallinsk polymorf av et bazedoksifenacetat | |
| NO20071254L (no) | Fremgangsmate for fremstilling av irbesartan og mellomprodukter derav. | |
| ATE517873T1 (de) | 6-oxo-1,6-dihydropyrimidin-2-yle bei der behandlung proliferativer krankheiten | |
| NO20081621L (no) | Tetrahydrokinoliner, syntese og intermediater | |
| ATE441646T1 (de) | 5-ht4-rezeptoragonistenverbindungen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |